Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A detailed examination of the PEARL rapamycin trial's enrollment biases, statistical caveats, short follow-up, generalizability gaps, and conflict-of-interest considerations that temper its headline findings.
Read clinical reviewA detailed breakdown of the PEARL trial's randomization, blinding, endpoint selection, estimand framework, and statistical approach for rapamycin in healthy aging adults.
Read clinical reviewA deep-dive into the economic dimensions of the PEARL rapamycin RCT: what the trial data suggest about cost per QALY, list versus net pricing, payer coverage logic, and how individual patients should think about relative value.
Read clinical reviewDeep dive into the PEARL trial's follow-up and extension findings for weekly rapamycin in healthy adults, covering durability of effects, safety signals, and long-term outcome data.
Read clinical reviewA detailed breakdown of the PEARL trial's rapamycin results in healthy older adults, including effect sizes, secondary endpoints, immune markers, and time-course patterns from this landmark 2024 Aging Cell RCT.
Read clinical reviewDetailed breakdown of the PEARL trial's pre-specified and post-hoc subgroup analyses by age, sex, BMI, and baseline biomarkers, revealing which healthy adults benefited most from low-dose rapamycin.
Read clinical reviewA clinical-practice analysis of the PEARL trial, the first substantial RCT of weekly rapamycin in healthy older adults, and what its findings mean for prescribing, guidelines, and patient selection today.
Read clinical review